345965-52-8

Usage

Uses

Used in Organic Chemistry:
1-(4-Bromophenyl)cyclopropanecarboxylic acid is used as a synthetic intermediate for the preparation of various organic compounds. Its cyclopropane ring and carboxylic acid group provide opportunities for further functionalization and modification, facilitating the development of new chemical entities.
Used in Pharmaceutical Industry:
1-(4-Bromophenyl)cyclopropanecarboxylic acid is used as a key component in the synthesis of pharmaceuticals. Its unique structure and reactivity can be leveraged to create novel drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
1-(4-Bromophenyl)cyclopropanecarboxylic acid is used as a precursor in the development of agrochemicals, such as pesticides and herbicides. Its chemical properties can be exploited to design effective and environmentally friendly products for agricultural use.
Used in Materials Science:
1-(4-Bromophenyl)cyclopropanecarboxylic acid is used as a building block for the creation of new materials with specific properties. Its cyclopropane ring and functional groups can be incorporated into polymers, coatings, or other materials to enhance their performance or introduce new functionalities.

InChI:InChI=1/C10H9BrO2/c11-8-3-1-7(2-4-8)10(5-6-10)9(12)13/h1-4H,5-6H2,(H,12,13)

Upstream product

• 107-21-1 ethylene glycol 
• 124276-67-1 1-(4-bromophenyl)cyclopropanecarbonitrile 
• 133017-10-4 Butyl 2-(4-bromophenyl)acetate 
• 16532-79-9 4-Bromophenylacetonitrile 
• 107-04-0 1-Bromo-2-chloroethane 
• 106-93-4 ethylene dibromide 
• 6120-95-2 1-phenyl-1-cyclopropane carboxylic acid 

Downstream Products

• 847361-67-5 1-(4-bromophenyl)cyclopropanecarboxamide 
• 1215205-50-7 ethyl 1-(4-bromophenyl)cyclopropane-1-carboxylate 
• 1394819-49-8 1-[4-((E)-2-cyanoethenesulfonyl)phenyl]cyclopropanecarboxylic acid 
• 1394819-55-6 1-[4-((E)-2-cyanoethenesulfonyl)phenyl]cyclopropanecarboxylic acid 4-fluorobenzylamide 
• 1394819-56-7 1-[4-((E)-2-cyanoethenesulfonyl)phenyl]cyclopropanecarboxylic acid cyclohexylamide 
• 1426925-13-4 1-(4-(2-chloro-5-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxylmethyl)tetrahydro-2H-pyran-2-yl)benzyl)phenyl)cyclopropanecarbaldehyde O-methyl oxime 
• 1147531-61-0 1-(4-bromophenyl)cyclopropane-1-carbaldehyde 
• 1426925-14-5 1-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropane carbaldehyde 
• 1426925-15-6 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(1-formyl cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1426925-16-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-((4-(1-(methoxyimino)methyl)cyclopropyl)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 1396007-80-9 {5-[4'-(1-methanesulfonylaminocarbonyl-cyclopropyl)biphenyl-4-yl]-3-methyl-3H-[1,2,3]triazol-4-yl}carbamic acid (R)-1-(3-trifluoromethylphenyl)ethyl ester 
• 1396007-78-5 {5-[4'-(1-methanesulfonylaminocarbonyl-cyclopropyl)biphenyl-4-yl]-3-methyl-3H-[1,2,3]triazol-4-yl}carbamic acid (R)-1-phenyl-ethyl ester 
• 1396007-52-5 {3-[4'-(1-methanesulfonylaminocarbonyl-cyclopropyl)-biphenyl-4-yl]-5-methyl-3H-[1,2,3]triazol-4-yl}-carbamic acid (R)-1-phenyl-ethyl ester 
• 1402207-82-2 1-(4'-{3-Methyl-4-[6-(2-methyl-phenyl)-pyridin-2-ylamino]-isoxazol-5-yl}-biphenyl-4-yl)-cyclopropanecarboxylic acid ethyl ester 

Relevant academic research and scientific papers

Preparation method of arylcyclopropane compound

The present invention discloses a method for preparing an arylcyclopropane compound, 1.0eq phenylacetonitrile and 1.1eq 1-bromo-2-chloroethane as the starting material, N, N- dimethylacetamide as a solvent, solvent dosage of 10V, plus 2.5eq sodium hydride

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

NOVEL SGLT INHIBITORS

The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synt

General and cost-effective synthesis of 1-heteroaryl/arylcycloalkylamines and their broad applications

A general and cost-effective route has been developed to synthesize 1-heteroarylsubstituted cycloalkylamines from readily available heteroarylacetate in good yields. This synthesis features a LHMDS promoted cyclization and one-pot hydrolysis/Curtius rearr

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

NOVEL PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION INCLUDING SAME AS AN ACTIVE INGREDIENT

The present invention relates to a compound represented by formula (I) for inhibiting the activity of diacylglycerol O-acyltransferase type 1 (DGAT1), and pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention may be used effectively in the treatment or prevention of a disease or condition mediated by the activity of DGAT1 such as obesity, type II diabetes, dyslipidemia, metabolic syndrome, and the like, without any adverse effects: wherein A, B, X, and R5 to R7 are the same as defined in the specification.

SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY

The present invention relates to compounds of formula (I), which have valuable pharmacological properties, in particular are activators of AMPK and which are therefore useful in the treatment of certain disorders that can be prevented or treated by activation of this receptor. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

TETRAHYDROTHIAZEPINE DERIVATIVE

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1: General formula (I) wherein R1 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; R2 independently represents a halogen atom or a C1-C6 alkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C1-C6 alkyl groups, and so forth.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.